Abstract 3435
Background
Adult primary malignant brain tumours are rare; however, they have a devastating impact and a poor prognosis (Ford et al., 2012). For the past seven years the National Cancer Patient Experience Survey (Quality Health, 2014) has reported the care of brain tumour patients as being less positive compared to other cancer sites, possibly due to unmet care needs. The Aims of this research were: - To explore registered medical nurses’ experiences of the care needs of adult patients with a primary brain tumour. - To identify possible gaps in knowledge and skills that limit the provision of optimal care.
Methods
The project adopted a qualitative methodological approach using semi-structured interviews to collect and analyse data to reflect the experiences of medical nurses’ in the aforementioned care context. Three participants volunteered, who met the inclusion/exclusion criteria. Participants were registered nurses who had worked on the oncology/haematology Triage Unit for 12 months or more so that they had meaningful reflection.
Results
Themes emerged from the collection and analysis of data. Three main themes emphasised that the experience was: challenging; involved holistic care and depended on nurses’ knowledge and experience. Published literature identified that brain tumour patients were different to other cancer patients because they require more nursing time to address their complex care needs. The findings highlighted that senior nurses were significantly more knowledgeable, holistic and aware of patient needs.
Conclusions
Junior nurses felt they had very limited experience, confidence or knowledge to care for adult patients with a primary brain tumour. They acknowledged that education and training was essential to allow staff involved in the care of adult patients with a primary brain tumour to feel confident enough to be able to assess and care for the complex needs of this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birmingham City University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract